Industry veteran Renata Berardocco appointed to spearhead growth in key Latin American countries

Miami, FL, December 9, 2024 -- Velocity Clinical Research, the leading fully integrated clinical site organization, today announced its strategic expansion into Latin America with the appointment of Renata Berardocco as Executive Vice President and Managing Director for the region. This move marks a significant milestone in Velocity's global growth strategy, following its successful expansion in Europe.

Latin America represents 10% of the world's clinical research sites, making it a critical focus for Velocity's expansion plans. The company's entry into this market is poised to revolutionize the landscape for US Medtech companies seeking world-class clinical research services in the region.

Paul Evans, Velocity's President and Chief Executive, commented on the strategic move: "Having established strong traction in Europe, Latin America is the natural next step for our growth-through-acquisition strategy. Renata's wealth of experience in building and managing multisite networks aligns perfectly with our vision for the region. Under her leadership, we will focus primarily on Brazil, Argentina, and Mexico, which account for approximately 70% of the Latin American population."

Renata Berardocco brings nearly two decades of senior leadership experience to her new role at Velocity. Most recently, she led Clinical Operations Delivery and Clinical Projects at Fortrea, where she drove significant expansion in Latin American operations. Her appointment underscores Velocity's commitment to leveraging local expertise to drive global growth.

"I understand all too well the clinical trial process and how critical patient recruitment is," said Berardocco. "Velocity's fast growth and commitment to technology make it a formidable force in clinical research. I look forward to bringing the Velocity model to Latin America and, conversely, bringing the advantages of the Latin American region to Velocity to deliver meaningful improvements to our patients, Sponsors, and CROs globally."

Velocity's expansion into Latin America follows a period of rapid growth for the company. In just 24 months, Velocity has successfully scaled to 17 European sites across three countries, employing a team of 150 in the region. Today, the company boasts over 90 sites and employs 1,500 people worldwide, including 220 Principal Investigators.

This strategic move is expected to significantly impact the market for world-class clinical research sites in Latin America. By leveraging Velocity's integrated model and technological expertise, US Medtech companies will gain access to large patient populations and exceptional Principal Investigators in key markets such as Brazil, Mexico, and Argentina.

For US Medtech medical device companies looking to accelerate their clinical trials and expand their global reach, Velocity's entry into Latin America presents an unparalleled opportunity. The company's proven track record of rapid scaling and its commitment to quality and efficiency positions it as the partner of choice for clinical research in the region.

About Velocity Clinical Research Velocity Clinical Research is the leading integrated organization of clinical research sites. With 90 locations and over 220 investigators, Velocity partners with pharmaceutical and biotechnology companies to research new drugs, medical devices, diagnostics, and combination products that could improve human health and well-being. Velocity offers unified research site solutions to efficiently deliver the right patients, investigators, and research staff for clinical trials across the US and Europe. The company also operates a technology center in India, ushering in a new era in clinical research through the development of innovative systems to leverage comprehensive site, patient, and historical performance data. To learn more about how Velocity delivers high-quality data, exemplary patient care, and unparalleled efficiency for clinical trials at any scale, visit VelocityClinical.com.